J. Harvey Harvey Turner

Prof. J. Harvey Harvey Turner


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2010 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
PCPhillip G. Claringbold
Phillip G. Claringbold
PBPaul A. Brayshaw
Paul A. Brayshaw
RPRichard A. Price
Richard A. Price
JTJ. Harvey Harvey Turner
J. Harvey Harvey Turner

1 November 2012 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
PCPhillip G. Claringbold
Phillip G. Claringbold
RPRichard A. Price
Richard A. Price
JTJ. Harvey Harvey Turner
J. Harvey Harvey Turner
We conducted a phase I-II clinical trial to assess the safety and efficacy of combining lutetium-177 (177Lu)-octreotate with capecitabine and temozolomide in treating advanced low-grade neuroendocrine tumors (NETs). All 35 patients received fixed activities of 7.8 GBq 177Lu-octreotate each 8 weeks, with 14 days of capecitabine 1500 mg/m2 for 4 cycles. In phase I, successive cohorts of patients received escalating doses of temozolomide in groupings of 100, 150, and 200 mg/m2 in the last 5 days of each capecitabine cycle. In phase II, patients were treated with 200 mg/m2 temozolomide. Treatment was well tolerated in all dosage groups. No dose-limiting grade 2, 3, or 4 toxicities were seen in cohorts 1 (100 mg/m2) or 2 (150 mg/m2). Twenty-eight patients completed treatment at the 200 mg/m2 temozolomide level. Adverse events were mild to moderate. The commonest toxicities were transient nausea grade 2 (18%), grade 3 (3%), thrombocytopenia grade 2 (24%), and neutropenia grade 3 (6%). There were no grade 4 events. Thirty-four patients were evaluable for tumor response. Overall, complete response (CR) was achieved in 15% (95% CI 3–27); partial response (PR), in 38% (95% CI 22–55); stable disease (SD), in 38% (95% CI 22–55); and 3 patients failed to respond to treatment. Median progression free survival (PFS) was 31 months (95% CI 21–33), and median overall survival (OS) has not been reached with 90% surviving at 24 months follow-up (range 21–30). Overall objective response rate (ORR) in patients with gastroenteropancreatic NETs showed CR 16% (95% CI 3–28), PR 41% (95% CI 24–58), SD 37% (95% CI 21–54), and PD 6% (95% CI 0–15). Response rates were higher in patients with gastropancreatic NETs than in those with bowel primaries (enteric-NETs); CR 18% versus 13%, PR 64% versus 13%, SD 12% versus 67%. 177Lu-octreotate, in combination with capecitabine and temozolomide, is well tolerated in patients with advanced low-grade NETs, and shows substantial tumor control rates.

11 February 2018 in Diagnostics
Verified
Journal Article
Open access
PDF file
NLNat Lenzo
Nat Lenzo
DMDanielle Meyrick
Danielle Meyrick
JTJ. Harvey Harvey Turner
J. Harvey Harvey Turner
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. 68Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of 68Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), 68Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. 68Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA (177Lu-PSMA) and alpha-emitter Actinium-225 PSMA (225Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology.

1 November 2018 in British Journal of Radiology
Verified
Journal Article
Closed access
JTJ. Harvey Harvey Turner
J. Harvey Harvey Turner
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomized controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177 lutetium-DOTA-octreotatepeptide receptor radionuclide therapy (PRRT), of midgut NETs was established. Multicentre Phase 2 studies of 68-gallium/177 lutetium-PSMA theranostic approaches to management of end-stage metastatic castrate-resistant prostate cancer (mCRPC), are also very encouraging. However, the retrospective uncontrolled data currently available are inadmissible for formal regulatory agency evaluation. The challenge is to engage with oncologists and urologists, and to collaborate with the pharmaceutical industry, to design and perform the controlled clinical trials required for regulatory approval, and eventual reimbursement for theranostic nuclear oncology procedures. Strategies to facilitate timely establishment of an ev...

1 August 2015 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
PCPhillip G. Claringbold
Phillip G. Claringbold
JTJ. Harvey Harvey Turner
J. Harvey Harvey Turner
Objective: To establish the optimal safe dose of everolimus in combination with 177Lu-octreotate peptide receptor radionuclide therapy (PRRT) of advanced progressive gastro-entero pancreatic neuroendocrine tumors (GEP-NETs) and to define dose-limiting toxicity. Patients and Methods: Patients with advanced unresectable progressive well-differentiated GEP-NETS avid for 68Ga-octreotate on positron emission tomography–computed tomography imaging underwent PRRT with four cycles of 7.8 GBq 177Lu-octreotate at 8 week intervals. Successive cohorts of 3 patients received escalating doses of everolimus comprising 5, 7.5, and 10 mg daily for 24 weeks. Results: Sixteen patients comprised 4 at 5 mg, 9 at 7.5 mg, and 3 at 10 mg everolimus. Patient cohorts at 5 and 7.5 mg received 83% and 80% of the total planned dose of everolimus over 24 weeks. All patients required dose reduction or complete cessation of everolimus at the 10 mg level, which induced neutropenia and thrombocytopenia, and reduced creatinine clearance. The overall response rate was 44% (7 of 16 patients), and no patient progressed over the 6 month period of treatment. Four of 5 pancreatic NET patients achieved PR 80%. No patient progressed on study. Conclusion: In combination, PRRT with 177Lu-octreotate, the maximum tolerated dose of everolimus is 7.5 mg daily.

1 April 2014 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
PCPhillipe J. Calais
Phillipe J. Calais
JTJ. Harvey Harvey Turner
J. Harvey Harvey Turner